Clin2Atlas
AtlasBrain & nervesNeurological disorders

Parkinson's disease

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Selegiline approved (FDA)1996 — Cabergoline approved (FDA)1997 — Ropinirole approved (FDA)1997 — Pramipexole approved (FDA)1997 — Tolcapone approved (FDA)1998 — Entacapone approved (FDA)1998 — Rivastigmine approved (FDA)2000 — Ioflupane approved (FDA)2001 — Apomorphine approved (FDA)2005 — Rasagiline approved (FDA)2006 — Rotigotine approved (FDA)2015 — Safinamide approved (FDA)2016 — Opicapone approved (FDA)2016 — Pimavanserin approved (FDA)
1989: Drug approval — Selegiline approved (FDA). 1996: Drug approval — Cabergoline approved (FDA). 1997: Drug approval — Ropinirole approved (FDA). 1997: Drug approval — Pramipexole approved (FDA). 1997: Drug approval — Tolcapone approved (FDA). 1998: Drug approval — Entacapone approved (FDA). 1998: Drug approval — Rivastigmine approved (FDA). 2000: Drug approval — Ioflupane approved (FDA). 2001: Drug approval — Apomorphine approved (FDA). 2005: Drug approval — Rasagiline approved (FDA). 2006: Drug approval — Rotigotine approved (FDA). 2015: Drug approval — Safinamide approved (FDA). 2016: Drug approval — Opicapone approved (FDA). 2016: Drug approval — Pimavanserin approved (FDA)

What's being tested now

2002: 1 trials started2003: 1 trials started2006: 2 trials started2009: 3 trials started2011: 5 trials started2012: 3 trials started2013: 5 trials started2014: 7 trials started2015: 3 trials started2016: 10 trials started2017: 17 trials started2018: 6 trials started2019: 19 trials started2020: 28 trials started2021: 60 trials started2022: 58 trials started2023: 86 trials started2024: 185 trials started2025: 268 trials started2026: 252 trials started201020202026268

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 945 active Parkinson Disease, Idiopathic trials on Clin2 →

Related

Alzheimer's disease and other dementiasIdiopathic epilepsyMultiple sclerosisMotor neuron diseaseOther neurological disorders

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.